Cyrus Biotechnology to Present Its Novel IgG-degrading IdeS Enzyme Development Candidates for Autoimmune Indications at PepTalk Conference in San Diego

Director of Discovery Dr. Erik Procko recently performed a presentation on Cyrus’ novel IgG-degrading IdeS enzyme development candidates at PepTalk Conference San Diego on January 16th. The article can be found via the following link: https://www.businesswire.com/news/home/20240116136157/en/Cyrus-Biotechnology-to-Present-Its-Novel-IgG-degrading-IdeS-Enzyme-Development-Candidates-for-Autoimmune-Indications-at-PepTalk-Conference-in-San-Diego/

OpenFold AI Research Consortium Welcomes 4 New Members: Bayer, Dassault, CHARM Therapeutics and BaseCamp Research

OpenFold, a non-profit artificial intelligence (AI) research consortium whose goal is to develop free and open source software tools for biology and drug discovery, today announced the addition of four new industry members: Bayer, Dassault Systèmes, CHARM Therapeutics, and BaseCamp Research Ltd. OpenFold, a consortium of academic and industry partners founded in February 2022, is a […]

‘Decoy’ Protein Offers New Treatment Approach For Covid-19 – (Forbes.com)

Recently William Haseltine wrote an excellent article on Forbes regarding ACE2 research and the development of therapeutics for SARS-Cov2. The article includes a link to research performed by Cyrus scientists Erik Procko and Kui Chan. If you would like to read the articles, please feel free to follow the links below: ‘Decoy’ Protein Offers New […]

Cyrus Biotechnology CEO Lucas Nivon featured in Fierce Biotech Webinar

Date:  Thursday, February 3, 2022 Time:  2pm ET / 11am PT Duration:  1 Hour Sign up here to go to the webinar Improving the discovery of novel drugs with artificial intelligence Last year, Toronto-based Deep Genomics used artificial intelligence to scan 200,000 genomes from people with a variety of diseases, and in so doing identified a disease target—Wilson’s—as […]

Cyrus Biotechnology’s COVID therapeutic lead, ACE2.v2.4, strongly binds and neutralizes SARS-CoV-2 omicron variant potentially providing long term protection

SEATTLE, WA – (BUSINESS WIRE) – Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary platform for biologics discovery that combines software, AI and large-scale parallel protein screening, today announced that its pre-clinical stage COVID therapeutic lead molecule, ACE2.v2.4 strongly binds the spike protein of SARS-CoV-2 variant of concern (VOC) omicron. ACE2.v2.4 was engineered […]

Cyrus Biotechnology Announces $18M Financing and Acquisition of Orthogonal Biologics to Form an Integrated Software-Driven Pre-Clinical-Stage Drug Discovery Firm – (Businesswire)

SEATTLE, WA December 6, 2021 — Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary software platform for biologics discovery, today announced the closing of a $18M Series B financing and acquisition of Orthogonal Biologics, a deep mutational scanning protein engineering spin-out from the University of Illinois at Urbana Champaign. The financing includes investments […]

Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins

– First collaboration program, leveraging Cyrus’ de novo computational approach to create proprietary IL-2 protein agonist targeting autoimmune and other deleterious immune conditions- -Preclinical data demonstrate synergistic activity of ImmTOR in combination with IL-2 mutein to increase the level and durability of Treg expansion- – Unlocking a new generation of innovative biologic therapeutics with the potential […]